What You Should Know:
- Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution.
- This new product is the only single-cell high-throughput solution for measuring genome-wide copy number variants (CNVs) on the market and is designed to fulfill important needs in the critical areas of therapeutic development oncology research.
Advancing Genomic Integrity Analysis with Mission Bio’s Tapestri Genome Integrity CNV Solution
Genome-editing and stem cell therapies hold great potential for treating complex diseases but are often challenged by concerns surrounding genomic instability. The U.S. Food and Drug Administration (FDA) has recently emphasized the importance of assessing genomic integrity, including the detection of chromosomal abnormalities such as copy number variations (CNVs), to ensure clinical safety. Traditional techniques like g-banding have proven inadequate due to their low throughput, which limits their ability to analyze a sufficient number of cells for detecting aberrations.
In oncology, researchers face similar obstacles when attempting to unlock the potential of CNVs as prognostic or therapeutic markers related to tumor evolution, immune evasion, and therapeutic resistance. Current bulk techniques provide only a limited view of CNV-based clonal architecture, hindering progress in these areas.
Mission Bio’s Tapestri Genome Integrity CNV Solution addresses these challenges, offering a high-throughput, single-cell multiomic platform that enables comprehensive genome-wide CNV analysis. This solution provides:
– For CGT developers: Improved assay throughput for detecting adverse chromosomal events and simultaneously measuring genome-editing outcomes.
– For oncology researchers: The ability to assess cell-to-cell aneuploidy and CNV events across the genome, with the potential to co-measure single nucleotide variations (SNVs) and focal CNVs.
By enabling a detailed characterization of clonal heterogeneity in tumors, Tapestri empowers researchers to better understand tumorigenesis and therapy resistance.
According to Dr. Teresa Davoli of the NYU School of Medicine’s Institute for Systems Genetics, “Mission Bio’s Tapestri Platform provided the high throughput and sensitivity we needed for investigating chromosomal instability and aneuploidy in tumors.”
The Tapestri Genome Integrity CNV Solution will be featured at the 31st Annual European Society of Gene & Cell Therapy Meeting, taking place from October 22–25 in Rome, as a key highlight of Mission Bio’s latest innovations.
